Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

liarozole

An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits… Expand
National Institutes of Health

Related topics

Related topics

11 relations

Broader (5)

Androgen AntagonistsAntineoplastic Agents, HormonalDermatologic AgentsEnzyme Inhibitors
Expand
Liarozole HydrochlorideNCIt Antineoplastic Agent Terminologyliarozole fumarate

Narrower (3)

LiazalR 085246R 75251

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double‐blind, randomized, active‐controlled study
Background  Liarozole, a retinoic acid metabolism blocking agent, has been granted orphan drug status for congenital ichthyosis… Expand
Highly Cited
2001
Highly Cited
2001
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double‐blind, placebo‐controlled study
Background Palmoplantar pustular psoriasis (PPP) is a chronic, relapsing condition often recalcitrant to therapy. Synthetic… Expand
Highly Cited
1999
Highly Cited
1999
Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity.
1α,25-Dihydroxyvitamin D3[ 1,25-(OH)2D3] inhibits the proliferation of many cancer cells in culture, but not the aggressive human… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Review
1998
Review
1998
The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
Although significant advances have been made in the treatment of some malignancies, the prognosis of patients with metastatic… Expand
1998
1998
The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin
The imidazole derivative liarozole is a potent inhibitor of cytochrome P450‐dependent 4‐hydroxyla‐tion of endogenous all‐trans… Expand
Highly Cited
1998
Highly Cited
1998
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
OBJECTIVES To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed… Expand
1995
1995
Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells.
Liarozole has been reported to inhibit P450 enzymes responsible for the catabolism of retinoic acid. This suggests that it may… Expand
Review
1993
Review
1993
Ketoconazole and liarozole in the treatment of advanced prostatic cancer
Background. Ketoconazole, an imidazole derivative, is an orally active antifungal agent. In high doses (400 mg three times a day… Expand
Highly Cited
1992
Highly Cited
1992
Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.
Liarozole is a new imidazole derivative with antitumoral properties. Effects of the compound alone and in combination with all… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
1992
Highly Cited
1992
Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE